High-risk, high-reward stocks are for investors looking for stocks that can offer dramatic upside in the market. Analysts are pointing to several small-cap names that could deliver strong gains if their clinical or commercial catalysts play out. Three stocks, including Inventiva (IVA), Pharming Group (PHAR), and Atai Life Sciences (ATAI), stand out for their breakthrough pipelines and upcoming milestones.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
1. Inventiva (IVA)
Inventiva is developing lanifibranor, one of the most closely watched drug candidates in the race to treat nonalcoholic steatohepatitis (NASH), a multibillion-dollar market with limited approved therapies. The company has significant upside potential if the drug is approved. Importantly, early data from the drug’s Phase III trial show improvements in fibrosis and liver function.
Turning to Wall Street, IVA stock has a Strong Buy consensus rating based on nine Buys assigned in the last three months. At $15.75, the average Inventiva stock price target implies upside potential of 193.3%.
2. Pharming Group (PHAR)
Pharming Group is already generating revenue from Joenja, its treatment for activated PI3K delta syndrome (APDS), a rare immunodeficiency disorder. The company is considered a high‑risk, high‑reward opportunity because it is balancing steady commercial sales with a growing pipeline. Pharming is working to expand Joenja’s label and geographic reach, while also advancing additional rare-disease programs. Any positive regulatory or sales updates could drive the stock higher.
Wall Street’s consensus rating for PHAR stock is Strong Buy based on three unanimous Buys. The average analyst price target of $38.00 implies an upside potential of 192.76% from current levels.
3. Atai Life Sciences (ATAI)
Atai Life Sciences is a diversified mental-health biotech with programs in depression, anxiety, and addiction. It also owns a major stake in Beckley Psytech, which recently reported promising results for a psychedelic‑based depression treatment. With a broad pipeline, solid cash, and multiple late‑stage shots on goal, Atai is a classic high‑risk, high‑reward story where even one success could lead to major upside.
On TipRanks, analysts have a Strong Buy consensus rating on ATAI stock based on 11 Buys assigned in the past three months. Further, the average Atai Life Sciences price target of $14.80 per share implies 267.25% upside potential.
